Association of the improvement of Synovitis and Enthesitis with quality of life/patient reported outcomes in patients with PsA treated with Ixekizumab

Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors

Nash, Peter
Behrens, Frank
Orbai, Ana-Maria
Rathmann, Suchitrita S
Adams, David H
Benichou, Olivier
Deodhar, Atul

September 2018

Objective To conduct subset analyses of SPIRIT-P2 (Standard Protocol Items: Recommendations for Inte...

Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study

Mease, PJ
Gladman, DD
Deodhar, A
McGonagle, DG
Nash, P
Boehncke, W-H
Gottlieb, A
Xu, XL
Xu, S
Hsia, EC
Karyekar, CS
Helliwell, PS

July 2020

Objective To evaluate the effect of guselkumab on enthesitis and dactylitis in a phase II trial of p...

Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial.

Helliwell, Philip S
Mease, Philip
Kavanaugh, Arthur
Coates, Laura C
Ogdie, Alexis
Deodhar, Atul
Strand, Vibeke
Kricorian, Gregory
Liu, Lyrica X H
Collier, David
Gladman, Dafna D

July 2022

OBJECTIVE: We used the Study of Etanercept And Methotrexate in Combination or as Monotherapy in Subj...

Association between enthesitis and health-related quality of life in psoriatic arthritis in anti-TNF-naïve patients from two Phase 3 ustekinumab trials

McInnes, Iain B.
Puig, Lluis
Gottlieb, Alice B.
Ritchlin, Christopher
Song, Michael
You, Yin
Kafka, Shelly
Morgan, G. James
Rahman, Proton
Kavanaugh, Arthur

November 2019

Objective. Evaluate enthesitis, physical function, and health-related quality of life (HRQOL) among ...

Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis

Gladman, Dafna D
Orbai, Ana-Maria
Klitz, Uta
Wei, James C
Gallo, Gaia
Birt, Julie
Rathmann, Suchitrita
Shrom, David
Marzo-Ortega, Helena

February 2019

Abstract Background Ixekizumab improves signs/symptom...

Ixekizumab Provides Improvements Through 52 Weeks in Physical Function, Quality of Life, and Work Productivity in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis

Gottlieb, Alice
Husni, E
Lee, C
Lin, C
Burge, R
Shuler, C
Gladman, D

June 2017

Objectives: To evaluate whether the monoclonal antibody ixekizumab (IXE), a high-affinity interleuki...

Resolution of Enthesitis by Guselkumab and Relationships to Disease Burden: 1-Year Results of Two Phase-3 Psoriatic Arthritis Studies.

McGonagle, Dennis
McInnes, Iain B
Deodhar, Atul
Schett, Georg
Shawi, May
Kafka, Shelly
Karyekar, Chetan S
Kollmeier, Alexa P
Hsia, Elizabeth C
Xu, Xie L
Sheng, Shihong
Agarwal, Prasheen
Zhou, Bei
Ritchlin, Christopher T
Rahman, Proton
Mease, Philip J

April 2021

OBJECTIVE: To further characterize the effect of guselkumab, a selective interleukin-23p19-subunit i...

Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1).

Gottlieb, Alice B
Strand, Vibeke
Kishimoto, Mitsumasa
Mease, Philip
Thaçi, Diamant
Birt, Julie
Lee, Chin H
Shuler, Catherine L
Lin, Chen-Yen
Gladman, Dafna D

June 2018

Objective: To report patient-reported outcomes of patients with PsA treated with ixekizumab up to 52...

The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studies

Kavanaugh, Arthur
Gottlieb, Alice
Morita, Akimichi
Merola, Joseph F
Lin, Chen-Yen
Birt, Julie
Shuler, Catherine L
Hufford, Matthew M
Thaçi, Diamant

September 2019

OBJECTIVE:Determine the contribution of joint and skin improvements to health-related quality of lif...

Ixekizumab Improves Patient-Reported Outcomes Up to 52 Weeks in bDMARD-Naive Patients with Active Psoriatic Arthritis (SPIRIT-P1)

Gottlieb, Alice B
Strand, Vibeke
Kishimoto, Mitsumasa
Mease, Philip
Thaci, Diamant
Birt, Julie
Lee, Chin H.
Shuler, Catherine L.
Lin, Chen-Yen
Gladman, Dafna D.

October 2018

Objective: To report patient-reported outcomes of patients with PsA treated with ixekizumab up to 52...

Ixekizumab improves patient-reported outcomes in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitors: SPIRIT-P2 results to 52 weeks

Kavanaugh, A.
Marzo-Ortega, H.
Vender, R.
Wei, C. -C.
Birt, J.
Adams, D. H.
Benichou, O.
Lin, C. -Y.
Nash, P.

July 2019

ObjectiveTo report patient-reported outcomes (PROs) of ixekizumab-treated patients with psoriatic ar...

Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studies

McGonagle, Dennis
McInnes, Iain B.
Deodhar, Atul
Schett, Georg
Shawi, May
Kafka, Shelly
Karyekar, Chetan S.
Kollmeier, Alexa P.
Hsia, Elizabeth C.
Xu, Xie L.
Sheng, Shihong
Agarwal, Prasheen
Zhou, Bei
Ritchlin, Christopher T.
Rahman, Proton
Mease, Philip J.

November 2021

Objective: To further characterize the effect of guselkumab, a selective IL-23p19-subunit inhibito...

Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1).

van der Heijde, Désirée
Gladman, Dafna D
Kishimoto, Mitsumasa
Okada, Masato
Rathmann, Suchitrita S
Moriarty, Susan R
Shuler, Catherine L
Carlier, Hilde
Benichou, Olivier
Mease, Philip J

March 2018

OBJECTIVE: To evaluate the efficacy and safety of ixekizumab (IXE), an interleukin 17A antagonist, i...

Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1

Coates, LC
Kishimoto, M
Gottlieb, A
Shuler, CL
Lin, C-Y
Lee, CH
Mease, PJ

December 2017

Objective To evaluate the efficacy and safety of ixekizumab alone or with concomitant conventional d...

Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1.

Coates, Laura C
Kishimoto, Mitsumasa
Gottlieb, Alice
Shuler, Catherine L
Lin, Chen-Yen
Lee, Chin Hyok
Mease, Philip

January 2017

Objective: To evaluate the efficacy and safety of ixekizumab alone or with concomitant conventional ...

Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors

Nash, Peter
Behrens, Frank
Orbai, Ana-Maria
Rathmann, Suchitrita S
Adams, David H
Benichou, Olivier
Deodhar, Atul

September 2018

Objective To conduct subset analyses of SPIRIT-P2 (Standard Protocol Items: Recommendations for Inte...

Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study

Mease, PJ
Gladman, DD
Deodhar, A
McGonagle, DG
Nash, P
Boehncke, W-H
Gottlieb, A
Xu, XL
Xu, S
Hsia, EC
Karyekar, CS
Helliwell, PS

July 2020

Objective To evaluate the effect of guselkumab on enthesitis and dactylitis in a phase II trial of p...

Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial.

Helliwell, Philip S
Mease, Philip
Kavanaugh, Arthur
Coates, Laura C
Ogdie, Alexis
Deodhar, Atul
Strand, Vibeke
Kricorian, Gregory
Liu, Lyrica X H
Collier, David
Gladman, Dafna D

July 2022

OBJECTIVE: We used the Study of Etanercept And Methotrexate in Combination or as Monotherapy in Subj...

Association between enthesitis and health-related quality of life in psoriatic arthritis in anti-TNF-naïve patients from two Phase 3 ustekinumab trials

McInnes, Iain B.
Puig, Lluis
Gottlieb, Alice B.
Ritchlin, Christopher
Song, Michael
You, Yin
Kafka, Shelly
Morgan, G. James
Rahman, Proton
Kavanaugh, Arthur

November 2019

Objective. Evaluate enthesitis, physical function, and health-related quality of life (HRQOL) among ...

Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis

Gladman, Dafna D
Orbai, Ana-Maria
Klitz, Uta
Wei, James C
Gallo, Gaia
Birt, Julie
Rathmann, Suchitrita
Shrom, David
Marzo-Ortega, Helena

February 2019

Abstract Background Ixekizumab improves signs/symptom...

Ixekizumab Provides Improvements Through 52 Weeks in Physical Function, Quality of Life, and Work Productivity in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis

Gottlieb, Alice
Husni, E
Lee, C
Lin, C
Burge, R
Shuler, C
Gladman, D

June 2017

Objectives: To evaluate whether the monoclonal antibody ixekizumab (IXE), a high-affinity interleuki...

Resolution of Enthesitis by Guselkumab and Relationships to Disease Burden: 1-Year Results of Two Phase-3 Psoriatic Arthritis Studies.

McGonagle, Dennis
McInnes, Iain B
Deodhar, Atul
Schett, Georg
Shawi, May
Kafka, Shelly
Karyekar, Chetan S
Kollmeier, Alexa P
Hsia, Elizabeth C
Xu, Xie L
Sheng, Shihong
Agarwal, Prasheen
Zhou, Bei
Ritchlin, Christopher T
Rahman, Proton
Mease, Philip J

April 2021

OBJECTIVE: To further characterize the effect of guselkumab, a selective interleukin-23p19-subunit i...

Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1).

Gottlieb, Alice B
Strand, Vibeke
Kishimoto, Mitsumasa
Mease, Philip
Thaçi, Diamant
Birt, Julie
Lee, Chin H
Shuler, Catherine L
Lin, Chen-Yen
Gladman, Dafna D

June 2018

Objective: To report patient-reported outcomes of patients with PsA treated with ixekizumab up to 52...

The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studies

Kavanaugh, Arthur
Gottlieb, Alice
Morita, Akimichi
Merola, Joseph F
Lin, Chen-Yen
Birt, Julie
Shuler, Catherine L
Hufford, Matthew M
Thaçi, Diamant

September 2019

OBJECTIVE:Determine the contribution of joint and skin improvements to health-related quality of lif...

Ixekizumab Improves Patient-Reported Outcomes Up to 52 Weeks in bDMARD-Naive Patients with Active Psoriatic Arthritis (SPIRIT-P1)

Gottlieb, Alice B
Strand, Vibeke
Kishimoto, Mitsumasa
Mease, Philip
Thaci, Diamant
Birt, Julie
Lee, Chin H.
Shuler, Catherine L.
Lin, Chen-Yen
Gladman, Dafna D.

October 2018

Objective: To report patient-reported outcomes of patients with PsA treated with ixekizumab up to 52...

Ixekizumab improves patient-reported outcomes in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitors: SPIRIT-P2 results to 52 weeks

Kavanaugh, A.
Marzo-Ortega, H.
Vender, R.
Wei, C. -C.
Birt, J.
Adams, D. H.
Benichou, O.
Lin, C. -Y.
Nash, P.

July 2019

ObjectiveTo report patient-reported outcomes (PROs) of ixekizumab-treated patients with psoriatic ar...

Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studies

McGonagle, Dennis
McInnes, Iain B.
Deodhar, Atul
Schett, Georg
Shawi, May
Kafka, Shelly
Karyekar, Chetan S.
Kollmeier, Alexa P.
Hsia, Elizabeth C.
Xu, Xie L.
Sheng, Shihong
Agarwal, Prasheen
Zhou, Bei
Ritchlin, Christopher T.
Rahman, Proton
Mease, Philip J.

November 2021

Objective: To further characterize the effect of guselkumab, a selective IL-23p19-subunit inhibito...

Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1).

van der Heijde, Désirée
Gladman, Dafna D
Kishimoto, Mitsumasa
Okada, Masato
Rathmann, Suchitrita S
Moriarty, Susan R
Shuler, Catherine L
Carlier, Hilde
Benichou, Olivier
Mease, Philip J

March 2018

OBJECTIVE: To evaluate the efficacy and safety of ixekizumab (IXE), an interleukin 17A antagonist, i...

Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1

Coates, LC
Kishimoto, M
Gottlieb, A
Shuler, CL
Lin, C-Y
Lee, CH
Mease, PJ

December 2017

Objective To evaluate the efficacy and safety of ixekizumab alone or with concomitant conventional d...

Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1.

Coates, Laura C
Kishimoto, Mitsumasa
Gottlieb, Alice
Shuler, Catherine L
Lin, Chen-Yen
Lee, Chin Hyok
Mease, Philip

January 2017

Objective: To evaluate the efficacy and safety of ixekizumab alone or with concomitant conventional ...

Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors

Nash, Peter
Behrens, Frank
Orbai, Ana-Maria
Rathmann, Suchitrita S
Adams, David H
Benichou, Olivier
Deodhar, Atul

September 2018

Objective To conduct subset analyses of SPIRIT-P2 (Standard Protocol Items: Recommendations for Inte...

Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study

Mease, PJ
Gladman, DD
Deodhar, A
McGonagle, DG
Nash, P
Boehncke, W-H
Gottlieb, A
Xu, XL
Xu, S
Hsia, EC
Karyekar, CS
Helliwell, PS

July 2020

Objective To evaluate the effect of guselkumab on enthesitis and dactylitis in a phase II trial of p...

Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial.

Helliwell, Philip S
Mease, Philip
Kavanaugh, Arthur
Coates, Laura C
Ogdie, Alexis
Deodhar, Atul
Strand, Vibeke
Kricorian, Gregory
Liu, Lyrica X H
Collier, David
Gladman, Dafna D

July 2022

OBJECTIVE: We used the Study of Etanercept And Methotrexate in Combination or as Monotherapy in Subj...

Association of the improvement of Synovitis and Enthesitis with quality of life/patient reported outcomes in patients with PsA treated with Ixekizumab

Abstract

Extracted data

Related items

Related items